Skip to Content
Merck
  • Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin.

Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin.

Nature biomedical engineering (2020-06-24)
Mari Saif, Wilhelmus J Kwanten, Jessica A Carr, Ivy X Chen, Jessica M Posada, Amitabh Srivastava, Juanye Zhang, Yi Zheng, Matthias Pinter, Sampurna Chatterjee, Samir Softic, C Ronald Kahn, Klaus van Leyen, Oliver T Bruns, Rakesh K Jain, Moungi G Bawendi
ABSTRACT

Monitoring the progression of non-alcoholic fatty liver disease is hindered by a lack of suitable non-invasive imaging methods. Here, we show that the endogenous pigment lipofuscin displays strong near-infrared and shortwave-infrared fluorescence when excited at 808 nm, enabling label-free imaging of liver injury in mice and the discrimination of pathological processes from normal liver processes with high specificity and sensitivity. We also show that the near-infrared and shortwave-infrared fluorescence of lipofuscin can be used to monitor the progression and regression of liver necroinflammation and fibrosis in mouse models of non-alcoholic fatty liver disease and advanced fibrosis, as well as to detect non-alcoholic steatohepatitis and cirrhosis in biopsied samples of human liver tissue.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-p62/SQSTM1 antibody produced in rabbit, ~1 mg/mL, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
Sudan Black B, certified by the Biological Stain Commission
Sigma-Aldrich
Carbon tetrachloride, anhydrous, ≥99.5%